Paper published in a journal (Scientific congresses and symposiums)
HCVerso2: a phase III study of faldaprevir plus deleobuvir and ribavirin for chronic HCV genotype 1b infection in treatment naïve patients including those ineligible for pegylated interferon
[en] In treatment-naïve, non-cirrhotic patients with HCV GT1b infection, faldaprevir + deleobuvir + ribavirin for 16 or 24 w resulted in comparable SVR 12 rates (76% vs 82%) with similar tolerability profiles. Patients with cirrhosis achieved SVR 12 of 74% (24w). The adjusted SVR rates for 16 or 24w in patients with or without cirrhosis were significantly higher than historical control.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Nelson, D
Andreone, P
Colombo, M
Calinas, F
Olveira, A
DELWAIDE, Jean ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
HCVerso2: a phase III study of faldaprevir plus deleobuvir and ribavirin for chronic HCV genotype 1b infection in treatment naïve patients including those ineligible for pegylated interferon